Solti Breast Cancer Research Group
Clinical trials sponsored by Solti Breast Cancer Research Group, explained in plain language.
-
New drug cocktail targets Hard-to-Treat breast cancer mutation
Disease control CompletedThis early-phase trial tested a new drug, ipatasertib, added to two existing breast cancer medicines (trastuzumab and pertuzumab) in 17 people with advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation). The main goal was to find the safest dose…
Phase: PHASE1 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New test may predict which breast cancer patients benefit from targeted drug
Disease control CompletedThis study looked at whether a test called RAD51-foci can predict how well the drug olaparib works in people with advanced HER2-negative breast cancer who have certain gene mutations (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D). About 65 participants received olaparib, and researcher…
Phase: PHASE2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Cancer-Killing virus plus immunotherapy shows promise in tough breast cancers
Disease control CompletedThis early study tested a combination of a modified herpes virus (T-VEC) and an immunotherapy drug (atezolizumab) in 28 women with aggressive breast cancer that did not fully disappear after standard chemotherapy. The virus was injected directly into tumors to kill cancer cells a…
Phase: EARLY_PHASE1 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 26, 2026 15:12 UTC